MedTrace Logo

Effects of Probiotics in Patients With Ulcerative Colitis

NCT00578799 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2021-01-25

No results posted yet for this study

Summary

This study is being conducted in patients who have been diagnosed with ulcerative colitis (UC), a form of inflammatory bowel disease (IBD) - a disease of the intestine.

The purpose of this study is to test the therapeutic (medical treatment) effects of daily consumption of Kyo-Dophilus (a commercially available dietary supplement often used by individuals with inflammatory bowel disease) on their UC. Kyo-Dophilus consists of three probiotic bacteria (beneficial bacteria to help maintain the balance of good bacteria in the intestine) to help treat inflammatory bowel disease caused by bad bacteria. Patients will still be maintained on their clinical standard of care for their UC as part of their participation in this study.

Conditions

Interventions

DIETARY_SUPPLEMENT

Kyo-Dophilus

5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening

DIETARY_SUPPLEMENT

placebo

placebo capsules (potato starch

Sponsors & Collaborators

  • Wakunaga Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Dwight M Nance, Ph.D · University of California, Irvine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00578799 on ClinicalTrials.gov